Correlation between gene mutation status and selected clinical features

Thyroid Adenocarcinoma (Primary solid tumor)

17 October 2014 | analyses__2014_10_17

Maintainer Information

Citation Information

Maintained by TCGA GDAC Team (Broad Institute/MD Anderson Cancer Center/Harvard Medical School)

Cite as Broad Institute TCGA Genome Data Analysis Center (2014): Correlation between gene mutation status and selected clinical features. Broad Institute of MIT and Harvard. doi:10.7908/C1QN65QW

Overview

Introduction

This pipeline computes the correlation between significantly recurrent gene mutations and selected clinical features.

Summary

Testing the association between mutation status of 11 genes and 17 clinical features across 398 patients, 9 significant findings detected with Q value < 0.25.

BRAF mutation correlated to 'NEOPLASM.DISEASESTAGE', 'PATHOLOGY.T.STAGE', 'PATHOLOGY.N.STAGE', 'HISTOLOGICAL.TYPE', and 'EXTRATHYROIDAL.EXTENSION'.
NRAS mutation correlated to 'PATHOLOGY.N.STAGE' and 'HISTOLOGICAL.TYPE'.
DNMT3A mutation correlated to 'Time to Death'.
ITGAL mutation correlated to 'NEOPLASM.DISEASESTAGE'.

Results

Overview of the results

Table 1. Get Full Table Overview of the association between mutation status of 11 genes and 17 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, 9 significant findings detected.


		Clinical Features	Time to Death	AGE	NEOPLASM DISEASESTAGE	PATHOLOGY T STAGE	PATHOLOGY N STAGE	PATHOLOGY M STAGE	GENDER	HISTOLOGICAL TYPE	RADIATIONS RADIATION REGIMENINDICATION	RADIATIONEXPOSURE	EXTRATHYROIDAL EXTENSION	COMPLETENESS OF RESECTION	NUMBER OF LYMPH NODES	MULTIFOCALITY	TUMOR SIZE	RACE	ETHNICITY
	nMutated (%)	nWild-Type	logrank test	Wilcoxon-test	Fisher's exact test	Fisher's exact test	Fisher's exact test	Fisher's exact test	Fisher's exact test	Fisher's exact test	Fisher's exact test	Fisher's exact test	Fisher's exact test	Fisher's exact test	Wilcoxon-test	Fisher's exact test	Wilcoxon-test	Fisher's exact test	Fisher's exact test
BRAF	238 (60%)	160	0.905 (1.00)	0.427 (1.00)	0.00078 (0.134)	0.00043 (0.0752)	0.000499 (0.0868)	0.132 (1.00)	0.293 (1.00)	1e-05 (0.00179)	0.0322 (1.00)	0.595 (1.00)	1e-05 (0.00179)	0.359 (1.00)	0.014 (1.00)	0.917 (1.00)	0.225 (1.00)	0.914 (1.00)	0.437 (1.00)
NRAS	34 (9%)	364	0.467 (1.00)	0.546 (1.00)	0.0343 (1.00)	0.153 (1.00)	0.000139 (0.0244)	0.474 (1.00)	0.839 (1.00)	7e-05 (0.0124)	0.61 (1.00)	1 (1.00)	0.191 (1.00)	0.689 (1.00)	0.00149 (0.255)	0.371 (1.00)	0.497 (1.00)	0.111 (1.00)	0.0625 (1.00)
DNMT3A	3 (1%)	395	0 (0)	0.134 (1.00)	0.0609 (1.00)	0.167 (1.00)	1 (1.00)	1 (1.00)	0.574 (1.00)	0.651 (1.00)	1 (1.00)	0.124 (1.00)	0.257 (1.00)	0.423 (1.00)	0.752 (1.00)	1 (1.00)		1 (1.00)	1 (1.00)
ITGAL	4 (1%)	394	0.0576 (1.00)	0.0159 (1.00)	0.0005 (0.0868)	0.147 (1.00)	0.348 (1.00)	1 (1.00)	0.052 (1.00)	0.709 (1.00)	1 (1.00)	1 (1.00)	0.00157 (0.267)	0.101 (1.00)		0.627 (1.00)	0.45 (1.00)	1 (1.00)	0.269 (1.00)
HRAS	14 (4%)	384	0.518 (1.00)	0.336 (1.00)	0.366 (1.00)	0.391 (1.00)	0.388 (1.00)	0.261 (1.00)	0.759 (1.00)	0.0212 (1.00)	1 (1.00)	1 (1.00)	0.689 (1.00)	0.199 (1.00)	0.745 (1.00)	0.792 (1.00)	0.732 (1.00)	0.0977 (1.00)	0.616 (1.00)
EIF1AX	6 (2%)	392	0.0822 (1.00)	0.0554 (1.00)	0.922 (1.00)	1 (1.00)	0.625 (1.00)	0.472 (1.00)	0.174 (1.00)	0.0714 (1.00)	1 (1.00)	1 (1.00)	1 (1.00)	0.281 (1.00)	0.487 (1.00)	0.666 (1.00)	0.474 (1.00)		1 (1.00)
NUP93	4 (1%)	394	0.912 (1.00)	0.508 (1.00)	0.637 (1.00)	0.736 (1.00)	0.348 (1.00)	0.658 (1.00)	1 (1.00)	0.0142 (1.00)	1 (1.00)	1 (1.00)	1 (1.00)	0.521 (1.00)	0.375 (1.00)	0.34 (1.00)	1 (1.00)	0.197 (1.00)	1 (1.00)
PPM1D	5 (1%)	393	0.924 (1.00)	0.155 (1.00)	0.22 (1.00)	0.315 (1.00)	1 (1.00)	1 (1.00)	0.605 (1.00)	1 (1.00)	1 (1.00)	1 (1.00)	0.114 (1.00)	0.357 (1.00)		1 (1.00)	0.521 (1.00)	1 (1.00)	1 (1.00)
KRAS	4 (1%)	394	0.875 (1.00)	0.456 (1.00)	1 (1.00)	0.207 (1.00)	0.625 (1.00)	1 (1.00)	0.576 (1.00)	0.466 (1.00)	1 (1.00)	1 (1.00)	1 (1.00)	0.421 (1.00)	0.307 (1.00)	1 (1.00)	0.743 (1.00)		1 (1.00)
DLC1	4 (1%)	394	0.0668 (1.00)	0.781 (1.00)	0.73 (1.00)	1 (1.00)	0.605 (1.00)	0.662 (1.00)	1 (1.00)	1 (1.00)	1 (1.00)	1 (1.00)	0.388 (1.00)	0.519 (1.00)	0.413 (1.00)	0.627 (1.00)	0.574 (1.00)	1 (1.00)	0.269 (1.00)
NLRP6	3 (1%)	395	0.659 (1.00)	0.435 (1.00)	0.79 (1.00)	0.168 (1.00)	0.605 (1.00)	0.132 (1.00)	1 (1.00)	0.653 (1.00)	1 (1.00)	1 (1.00)	1 (1.00)	1 (1.00)	0.337 (1.00)	0.598 (1.00)			1 (1.00)

'BRAF MUTATION STATUS' versus 'NEOPLASM.DISEASESTAGE'

P value = 0.00078 (Fisher's exact test), Q value = 0.13

Table S1. Gene #1: 'BRAF MUTATION STATUS' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients	STAGE I	STAGE II	STAGE III	STAGE IV	STAGE IVA	STAGE IVC
ALL	228	44	83	2	33	6
BRAF MUTATED	130	18	59	0	26	4
BRAF WILD-TYPE	98	26	24	2	7	2

Figure S1. Get High-res Image Gene #1: 'BRAF MUTATION STATUS' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

'BRAF MUTATION STATUS' versus 'PATHOLOGY.T.STAGE'

P value = 0.00043 (Fisher's exact test), Q value = 0.075

Table S2. Gene #1: 'BRAF MUTATION STATUS' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

nPatients	T1	T2	T3	T4
ALL	116	137	127	15
BRAF MUTATED	68	66	89	13
BRAF WILD-TYPE	48	71	38	2

Figure S2. Get High-res Image Gene #1: 'BRAF MUTATION STATUS' versus Clinical Feature #4: 'PATHOLOGY.T.STAGE'

'BRAF MUTATION STATUS' versus 'PATHOLOGY.N.STAGE'

P value = 0.000499 (Fisher's exact test), Q value = 0.087

Table S3. Gene #1: 'BRAF MUTATION STATUS' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients	0	1
ALL	188	169
BRAF MUTATED	98	119
BRAF WILD-TYPE	90	50

Figure S3. Get High-res Image Gene #1: 'BRAF MUTATION STATUS' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'BRAF MUTATION STATUS' versus 'HISTOLOGICAL.TYPE'

P value = 1e-05 (Fisher's exact test), Q value = 0.0018

Table S4. Gene #1: 'BRAF MUTATION STATUS' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients	OTHER SPECIFY	THYROID PAPILLARY CARCINOMA - CLASSICAL/USUAL	THYROID PAPILLARY CARCINOMA - FOLLICULAR (>= 99% FOLLICULAR PATTERNED)	THYROID PAPILLARY CARCINOMA - TALL CELL (>= 50% TALL CELL FEATURES)
ALL	6	280	83	29
BRAF MUTATED	3	193	15	27
BRAF WILD-TYPE	3	87	68	2

Figure S4. Get High-res Image Gene #1: 'BRAF MUTATION STATUS' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'BRAF MUTATION STATUS' versus 'EXTRATHYROIDAL.EXTENSION'

P value = 1e-05 (Fisher's exact test), Q value = 0.0018

Table S5. Gene #1: 'BRAF MUTATION STATUS' versus Clinical Feature #11: 'EXTRATHYROIDAL.EXTENSION'

nPatients	MINIMAL (T3)	MODERATE/ADVANCED (T4A)	NONE	VERY ADVANCED (T4B)
ALL	102	11	270	1
BRAF MUTATED	79	11	142	0
BRAF WILD-TYPE	23	0	128	1

Figure S5. Get High-res Image Gene #1: 'BRAF MUTATION STATUS' versus Clinical Feature #11: 'EXTRATHYROIDAL.EXTENSION'

'NRAS MUTATION STATUS' versus 'PATHOLOGY.N.STAGE'

P value = 0.000139 (Fisher's exact test), Q value = 0.024

Table S6. Gene #2: 'NRAS MUTATION STATUS' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

nPatients	0	1
ALL	188	169
NRAS MUTATED	27	5
NRAS WILD-TYPE	161	164

Figure S6. Get High-res Image Gene #2: 'NRAS MUTATION STATUS' versus Clinical Feature #5: 'PATHOLOGY.N.STAGE'

'NRAS MUTATION STATUS' versus 'HISTOLOGICAL.TYPE'

P value = 7e-05 (Fisher's exact test), Q value = 0.012

Table S7. Gene #2: 'NRAS MUTATION STATUS' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

nPatients	OTHER SPECIFY	THYROID PAPILLARY CARCINOMA - CLASSICAL/USUAL	THYROID PAPILLARY CARCINOMA - FOLLICULAR (>= 99% FOLLICULAR PATTERNED)	THYROID PAPILLARY CARCINOMA - TALL CELL (>= 50% TALL CELL FEATURES)
ALL	6	280	83	29
NRAS MUTATED	0	15	19	0
NRAS WILD-TYPE	6	265	64	29

Figure S7. Get High-res Image Gene #2: 'NRAS MUTATION STATUS' versus Clinical Feature #8: 'HISTOLOGICAL.TYPE'

'DNMT3A MUTATION STATUS' versus 'Time to Death'

P value = 0 (logrank test), Q value = 0

Table S8. Gene #7: 'DNMT3A MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

	nPatients	nDeath	Duration Range (Median), Month
ALL	396	13	0.0 - 158.8 (17.0)
DNMT3A MUTATED	3	1	1.0 - 7.7 (6.8)
DNMT3A WILD-TYPE	393	12	0.0 - 158.8 (17.2)

Figure S8. Get High-res Image Gene #7: 'DNMT3A MUTATION STATUS' versus Clinical Feature #1: 'Time to Death'

'ITGAL MUTATION STATUS' versus 'NEOPLASM.DISEASESTAGE'

P value = 5e-04 (Fisher's exact test), Q value = 0.087

Table S9. Gene #10: 'ITGAL MUTATION STATUS' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

nPatients	STAGE I	STAGE II	STAGE III	STAGE IV	STAGE IVA	STAGE IVC
ALL	228	44	83	2	33	6
ITGAL MUTATED	0	1	0	1	2	0
ITGAL WILD-TYPE	228	43	83	1	31	6

Figure S9. Get High-res Image Gene #10: 'ITGAL MUTATION STATUS' versus Clinical Feature #3: 'NEOPLASM.DISEASESTAGE'

Methods & Data

Input

Mutation data file = transformed.cor.cli.txt
Clinical data file = THCA-TP.merged_data.txt
Number of patients = 398
Number of significantly mutated genes = 11
Number of selected clinical features = 17
Exclude genes that fewer than K tumors have mutations, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Fisher's exact test

For binary or multi-class clinical features (nominal or ordinal), two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.

References

[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)

[2] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)

[3] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)

Made with Nozzle